Skip to content

Prevalence of IR in Overweight and Obese Adolescents

Prevalence and Risk Factors of Insulin Resistance in Overweight and Obese Adolescents

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05810883
Acronym
IR
Enrollment
50
Registered
2023-04-13
Start date
2023-05-11
Completion date
2025-08-30
Last updated
2023-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance

Brief summary

The aim of this study is to determine the prevalence of Insulin Resistance (IR) among overweight and obese adolescents using HOMA-IR scores and identify lifestyle risk factors in the IR and Non-IR group.

Interventions

DIAGNOSTIC_TESTBlood Tests; Serum Fasting Insulin and Glucose

Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR. Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Adolescents of ages ≥ 10-≤18 years, of both sexes who are Overweight (BMI \> 85th percentile) or Obese (BMI \> 95th percentile).

Exclusion criteria

* Obesity due to Secondary causes as Cushing disease or hypothyroid patients, and any other patients with Chronic illness.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants of the Obese or Overweight category with elevated Serum Fasting Insulin and Serum Fasting glucose scoresBaselineMeasuring Serum Fasting Insulin and Fasting Glucose levels to calculate HOMA-IR scores Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (Fasting Plasma Glucose (mmol/L) × Fasting Plasma Insulin (mU/L)/22.5) and defined as HOMA-IR ≥ 3.4 to Detect Prevalence of IR, higher scores indicating increased Insulin Resistance.

Secondary

MeasureTime frameDescription
Identifying Risk Factors for Insulin Resistance in each groupBaselineInformation on each individual gathered regarding Lifestyle and Nutritional Habits including Social/Economic condition, Family History for obesity, diabetes and hypertension, perinatal history, early feeding and detailed Nutritional History; including sugar, carbohydrate and fat consumption, Physical activity, sleep quality, psychological stressors and performance at school. Data will be gathered for each group; Insulin Resistant and Non-Insulin resistance to determine associations between the two.

Contacts

Primary ContactYara Mostafa, MBBS
yaramostafa9595@gmail.com+201064883673

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026